Cargando…
Neutralization against SARS-CoV-2 Delta/Omicron variants and B cell response after inactivated vaccination among COVID-19 convalescents
Emerging SARS-CoV-2 variants have made COVID-19 convalescents susceptible to re-infection and have raised concern about the efficacy of inactivated vaccination in neutralization against emerging variants and antigen-specific B cell response. To this end, a study on a long-term cohort of 208 particip...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Higher Education Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9898702/ https://www.ncbi.nlm.nih.gov/pubmed/36738428 http://dx.doi.org/10.1007/s11684-022-0954-x |
_version_ | 1784882483409453056 |
---|---|
author | Wang, Hao Yuan, Yu Wu, Bihao Xiao, Mingzhong Wang, Zhen Diao, Tingyue Zeng, Rui Chen, Li Lei, Yanshou Long, Pinpin Guo, Yi Lai, Xuefeng Wen, Yuying Li, Wenhui Cai, Hao Song, Lulu Ni, Wei Zhao, Youyun Ouyang, Kani Wang, Jingzhi Wang, Qi Liu, Li Wang, Chaolong Pan, An Li, Xiaodong Gong, Rui Wu, Tangchun |
author_facet | Wang, Hao Yuan, Yu Wu, Bihao Xiao, Mingzhong Wang, Zhen Diao, Tingyue Zeng, Rui Chen, Li Lei, Yanshou Long, Pinpin Guo, Yi Lai, Xuefeng Wen, Yuying Li, Wenhui Cai, Hao Song, Lulu Ni, Wei Zhao, Youyun Ouyang, Kani Wang, Jingzhi Wang, Qi Liu, Li Wang, Chaolong Pan, An Li, Xiaodong Gong, Rui Wu, Tangchun |
author_sort | Wang, Hao |
collection | PubMed |
description | Emerging SARS-CoV-2 variants have made COVID-19 convalescents susceptible to re-infection and have raised concern about the efficacy of inactivated vaccination in neutralization against emerging variants and antigen-specific B cell response. To this end, a study on a long-term cohort of 208 participants who have recovered from COVID-19 was conducted, and the participants were followed up at 3.3 (Visit 1), 9.2 (Visit 2), and 18.5 (Visit 3) months after SARS-CoV-2 infection. They were classified into three groups (no-vaccination (n = 54), one-dose (n = 62), and two-dose (n = 92) groups) on the basis of the administration of inactivated vaccination. The neutralizing antibody (NAb) titers against the wild-type virus continued to decrease in the no-vaccination group, but they rose significantly in the one-dose and two-dose groups, with the highest NAb titers being observed in the two-dose group at Visit 3. The NAb titers against the Delta variant for the no-vaccination, one-dose, and two-dose groups decreased by 3.3, 1.9, and 2.3 folds relative to the wild-type virus, respectively, and those against the Omicron variant decreased by 7.0, 4.0, and 3.8 folds, respectively. Similarly, the responses of SARS-CoV-2 RBD-specific B cells and memory B cells were boosted by the second vaccine dose. Results showed that the convalescents benefited from the administration of the inactivated vaccine (one or two doses), which enhanced neutralization against highly mutated SARS-CoV-2 variants and memory B cell responses. Two doses of inactivated vaccine among COVID-19 convalescents are therefore recommended for the prevention of the COVID-19 pandemic, and vaccination guidelines and policies need to be updated. ELECTRONIC SUPPLEMENTARY MATERIAL: Supplementary material is available in the online version of this article at 10.1007/s11684-022-0954-x and is accessible for authorized users. |
format | Online Article Text |
id | pubmed-9898702 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Higher Education Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-98987022023-02-06 Neutralization against SARS-CoV-2 Delta/Omicron variants and B cell response after inactivated vaccination among COVID-19 convalescents Wang, Hao Yuan, Yu Wu, Bihao Xiao, Mingzhong Wang, Zhen Diao, Tingyue Zeng, Rui Chen, Li Lei, Yanshou Long, Pinpin Guo, Yi Lai, Xuefeng Wen, Yuying Li, Wenhui Cai, Hao Song, Lulu Ni, Wei Zhao, Youyun Ouyang, Kani Wang, Jingzhi Wang, Qi Liu, Li Wang, Chaolong Pan, An Li, Xiaodong Gong, Rui Wu, Tangchun Front Med Research Article Emerging SARS-CoV-2 variants have made COVID-19 convalescents susceptible to re-infection and have raised concern about the efficacy of inactivated vaccination in neutralization against emerging variants and antigen-specific B cell response. To this end, a study on a long-term cohort of 208 participants who have recovered from COVID-19 was conducted, and the participants were followed up at 3.3 (Visit 1), 9.2 (Visit 2), and 18.5 (Visit 3) months after SARS-CoV-2 infection. They were classified into three groups (no-vaccination (n = 54), one-dose (n = 62), and two-dose (n = 92) groups) on the basis of the administration of inactivated vaccination. The neutralizing antibody (NAb) titers against the wild-type virus continued to decrease in the no-vaccination group, but they rose significantly in the one-dose and two-dose groups, with the highest NAb titers being observed in the two-dose group at Visit 3. The NAb titers against the Delta variant for the no-vaccination, one-dose, and two-dose groups decreased by 3.3, 1.9, and 2.3 folds relative to the wild-type virus, respectively, and those against the Omicron variant decreased by 7.0, 4.0, and 3.8 folds, respectively. Similarly, the responses of SARS-CoV-2 RBD-specific B cells and memory B cells were boosted by the second vaccine dose. Results showed that the convalescents benefited from the administration of the inactivated vaccine (one or two doses), which enhanced neutralization against highly mutated SARS-CoV-2 variants and memory B cell responses. Two doses of inactivated vaccine among COVID-19 convalescents are therefore recommended for the prevention of the COVID-19 pandemic, and vaccination guidelines and policies need to be updated. ELECTRONIC SUPPLEMENTARY MATERIAL: Supplementary material is available in the online version of this article at 10.1007/s11684-022-0954-x and is accessible for authorized users. Higher Education Press 2023-02-04 /pmc/articles/PMC9898702/ /pubmed/36738428 http://dx.doi.org/10.1007/s11684-022-0954-x Text en © Higher Education Press 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Research Article Wang, Hao Yuan, Yu Wu, Bihao Xiao, Mingzhong Wang, Zhen Diao, Tingyue Zeng, Rui Chen, Li Lei, Yanshou Long, Pinpin Guo, Yi Lai, Xuefeng Wen, Yuying Li, Wenhui Cai, Hao Song, Lulu Ni, Wei Zhao, Youyun Ouyang, Kani Wang, Jingzhi Wang, Qi Liu, Li Wang, Chaolong Pan, An Li, Xiaodong Gong, Rui Wu, Tangchun Neutralization against SARS-CoV-2 Delta/Omicron variants and B cell response after inactivated vaccination among COVID-19 convalescents |
title | Neutralization against SARS-CoV-2 Delta/Omicron variants and B cell response after inactivated vaccination among COVID-19 convalescents |
title_full | Neutralization against SARS-CoV-2 Delta/Omicron variants and B cell response after inactivated vaccination among COVID-19 convalescents |
title_fullStr | Neutralization against SARS-CoV-2 Delta/Omicron variants and B cell response after inactivated vaccination among COVID-19 convalescents |
title_full_unstemmed | Neutralization against SARS-CoV-2 Delta/Omicron variants and B cell response after inactivated vaccination among COVID-19 convalescents |
title_short | Neutralization against SARS-CoV-2 Delta/Omicron variants and B cell response after inactivated vaccination among COVID-19 convalescents |
title_sort | neutralization against sars-cov-2 delta/omicron variants and b cell response after inactivated vaccination among covid-19 convalescents |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9898702/ https://www.ncbi.nlm.nih.gov/pubmed/36738428 http://dx.doi.org/10.1007/s11684-022-0954-x |
work_keys_str_mv | AT wanghao neutralizationagainstsarscov2deltaomicronvariantsandbcellresponseafterinactivatedvaccinationamongcovid19convalescents AT yuanyu neutralizationagainstsarscov2deltaomicronvariantsandbcellresponseafterinactivatedvaccinationamongcovid19convalescents AT wubihao neutralizationagainstsarscov2deltaomicronvariantsandbcellresponseafterinactivatedvaccinationamongcovid19convalescents AT xiaomingzhong neutralizationagainstsarscov2deltaomicronvariantsandbcellresponseafterinactivatedvaccinationamongcovid19convalescents AT wangzhen neutralizationagainstsarscov2deltaomicronvariantsandbcellresponseafterinactivatedvaccinationamongcovid19convalescents AT diaotingyue neutralizationagainstsarscov2deltaomicronvariantsandbcellresponseafterinactivatedvaccinationamongcovid19convalescents AT zengrui neutralizationagainstsarscov2deltaomicronvariantsandbcellresponseafterinactivatedvaccinationamongcovid19convalescents AT chenli neutralizationagainstsarscov2deltaomicronvariantsandbcellresponseafterinactivatedvaccinationamongcovid19convalescents AT leiyanshou neutralizationagainstsarscov2deltaomicronvariantsandbcellresponseafterinactivatedvaccinationamongcovid19convalescents AT longpinpin neutralizationagainstsarscov2deltaomicronvariantsandbcellresponseafterinactivatedvaccinationamongcovid19convalescents AT guoyi neutralizationagainstsarscov2deltaomicronvariantsandbcellresponseafterinactivatedvaccinationamongcovid19convalescents AT laixuefeng neutralizationagainstsarscov2deltaomicronvariantsandbcellresponseafterinactivatedvaccinationamongcovid19convalescents AT wenyuying neutralizationagainstsarscov2deltaomicronvariantsandbcellresponseafterinactivatedvaccinationamongcovid19convalescents AT liwenhui neutralizationagainstsarscov2deltaomicronvariantsandbcellresponseafterinactivatedvaccinationamongcovid19convalescents AT caihao neutralizationagainstsarscov2deltaomicronvariantsandbcellresponseafterinactivatedvaccinationamongcovid19convalescents AT songlulu neutralizationagainstsarscov2deltaomicronvariantsandbcellresponseafterinactivatedvaccinationamongcovid19convalescents AT niwei neutralizationagainstsarscov2deltaomicronvariantsandbcellresponseafterinactivatedvaccinationamongcovid19convalescents AT zhaoyouyun neutralizationagainstsarscov2deltaomicronvariantsandbcellresponseafterinactivatedvaccinationamongcovid19convalescents AT ouyangkani neutralizationagainstsarscov2deltaomicronvariantsandbcellresponseafterinactivatedvaccinationamongcovid19convalescents AT wangjingzhi neutralizationagainstsarscov2deltaomicronvariantsandbcellresponseafterinactivatedvaccinationamongcovid19convalescents AT wangqi neutralizationagainstsarscov2deltaomicronvariantsandbcellresponseafterinactivatedvaccinationamongcovid19convalescents AT liuli neutralizationagainstsarscov2deltaomicronvariantsandbcellresponseafterinactivatedvaccinationamongcovid19convalescents AT wangchaolong neutralizationagainstsarscov2deltaomicronvariantsandbcellresponseafterinactivatedvaccinationamongcovid19convalescents AT panan neutralizationagainstsarscov2deltaomicronvariantsandbcellresponseafterinactivatedvaccinationamongcovid19convalescents AT lixiaodong neutralizationagainstsarscov2deltaomicronvariantsandbcellresponseafterinactivatedvaccinationamongcovid19convalescents AT gongrui neutralizationagainstsarscov2deltaomicronvariantsandbcellresponseafterinactivatedvaccinationamongcovid19convalescents AT wutangchun neutralizationagainstsarscov2deltaomicronvariantsandbcellresponseafterinactivatedvaccinationamongcovid19convalescents |